Oncología Hepática
University of Bologna
Bolonia, ItaliaPublicaciones en colaboración con investigadores/as de University of Bologna (10)
2024
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
JHEP Reports, Vol. 6, Núm. 7
2023
-
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome
Hepatology, Vol. 77, Núm. 5, pp. 1527-1539
2022
-
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
The Lancet, Vol. 399, Núm. 10319, pp. 61-116
2021
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3
-
Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study
Gastroenterology, Vol. 160, Núm. 4, pp. 1151-1163.e3
2020
-
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncology
-
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Liver International, Vol. 40, Núm. 6, pp. 1467-1476
-
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
Hepatology, Vol. 72, Núm. 1, pp. 198-212
2011
-
Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation
Hepatology, Vol. 54, Núm. 3, pp. 868-878